Table 1.
CGP57380 inhibits the ability of primary BC progenitors to serially replate
BC CML | DMSO, % | CGP57380 | IM, % | Dasatinib, % |
CML 1 | 39.5 | ND | 11 | 14.2 |
CML 2 | 7.1 | ND | 3.9 | — |
CML 3* | 51.7 | ND | 37.5 | — |
CML 4 | 10.8 | ND | 7.1 | — |
CML 5 | 11.8 | ND | 4.3 | — |
CML 6* | 53.2 | ND | 75 | 45.8 |
CML7 | 35.2 | ND | 35.6 | 39.9 |
CML11 | 70.0 | ND | 40.0 | — |
CD34+ BC cells from eight different individuals with BC were treated with DMSO, 10.0 μM CGP57380, 2.0 μM IM, or 150 nM dasatinib for 48 h before harvesting for the CFC assay, and subsequent serial replating assay. Values presented here represent the third serial replating efficiency relative to the first CFC readout. ND, no colonies detected.
BC CML samples harboring the T315I mutation.